Takeda, Neurocrine sign $2bn deal on potential therapies for psychiatric disorders
Takeda Pharmaceutical has entered into a more than $2bn worth deal with Neurocrine Biosciences to develop potential therapies for psychiatric disorders.
Takeda Pharmaceutical has entered into a more than $2bn worth deal with Neurocrine Biosciences to develop potential therapies for psychiatric disorders.
For the outstanding efficiency and scalability, high-performance liquid chromatography (HPLC) has been widely used for purification of high-quality APIs and intermediates in the pharmaceutical industry.
The new pureO3 Dissolved Ozone Sensor with Intelligent Sensor Management (ISM®) technology provides robust, reliable measurement with increased stability in pure water applications.
Financing co-led by ARCH Venture Partners and Cowen Healthcare Investments
IGY Life Sciences has entered into a collaboration with MMS Holdings, a data-focused clinical research organisation (CRO), to advance the development of its anti-CoV-2 therapeutic antibody IgY-110.
AbbVie has joined forces with Harbour BioMed (HBM), Utrecht University (UU), and Erasmus Medical Center (EMC) to develop a novel antibody therapeutic for the prevention and treatment of Covid-19.
Cullinan Oncology, LLC announced today the closing of a $98.5 million Series B financing, which will be used to support ongoing clinical trials across its small molecule and biologics portfolio.
Memo Therapeutics, an innovator in the field of antibody discovery and immune repertoire analysis, today announces that it has identified several SARS-CoV-2-specific virus-neutralizing antibodies with the potential for development as a Covid-19 immunotherapy.
AstraZeneca has joined forces with Accent Therapeutics for the development and commercialisation of advanced therapeutics targeting RNA-modifying proteins (RMPs) to treat cancer.
AgeX Therapeutics, a biotechnology company developing therapeutics for human aging and regeneration, and ImStem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell-derived mesenchymal stem cells (hES-MSC), today announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeX’s embryonic stem cell line ESI 053 to derive ImStem’s investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes.